Ondine Biomedical Inc. OBIMF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.84% | 28.59% | 37.78% | 35.90% | 16.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.84% | 28.59% | 37.78% | 35.90% | 16.63% |
| Cost of Revenue | 21.83% | 27.58% | 71.03% | 68.68% | 6.72% |
| Gross Profit | 23.42% | 29.14% | 21.07% | 19.43% | 22.81% |
| SG&A Expenses | 1.18% | 5.89% | -21.04% | -22.13% | 1.94% |
| Depreciation & Amortization | -10.70% | -6.42% | -8.31% | -9.65% | 2.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.77% | 32.68% | 49.63% | 47.57% | 54.03% |
| Operating Income | -27.08% | -33.01% | -50.84% | -48.76% | -58.14% |
| Income Before Tax | -28.61% | -34.61% | -50.21% | -48.14% | -60.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.61% | -34.61% | -50.21% | -48.14% | -60.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.61% | -34.61% | -50.21% | -48.14% | -60.02% |
| EBIT | -27.08% | -33.01% | -50.84% | -48.76% | -58.14% |
| EBITDA | -27.28% | -33.21% | -51.17% | -48.56% | -58.47% |
| EPS Basic | -5.77% | -11.00% | 6.82% | 7.41% | 11.11% |
| Normalized Basic EPS | -6.15% | -9.52% | 6.10% | 7.14% | 10.96% |
| EPS Diluted | -5.77% | -11.00% | 6.82% | 7.41% | 11.11% |
| Normalized Diluted EPS | -6.15% | -9.52% | 6.10% | 7.14% | 10.96% |
| Average Basic Shares Outstanding | 21.74% | 21.74% | 60.18% | 60.18% | 81.08% |
| Average Diluted Shares Outstanding | 21.74% | 21.74% | 60.18% | 60.18% | 81.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |